levodopa and benserazide

PreclinicalSmall molecule

UUniversity Hospital, Geneva

levodopa and benserazide is one of 14 small molecule programs targeting Aphasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AphasiaActive, not recruiting

AphasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Aphasia

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

2 2

Namenda

AbbVie

Approved

2 3

Keppra

Piracetam

1 5

Levodopa/carbidopa

Orion Corporation, Orion Pharma

Phase 3

1 6

Lexapro

AbbVie

Phase 2

1 7

Neflamapimod

EEIP Pharma Inc

Phase 2

—8

Inderal

WWyeth-Lederle Vaccines

Phase 1

1 9

Reminyl

WWim Janssens

Preclinical

1 10

Bendopa

MMerz Pharmaceuticals GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aphasia1 trial

Effect of Dopaminergic Medication on Recovery of Aphasia

Completed·UUniversity Hospital, Geneva·N/A·NCT00941265·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for levodopa and benserazide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — levodopa and benserazide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for levodopa and benserazide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Geneva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Geneva

levodopa and benserazide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aphasia1 trial

References

Drug Info

Quick Facts

Related News